CALL/NOVO-NORDISK B/1400/0.1/20.03.26 | Real-time BOERSE MUENCHEN 11:25:01 04/07/2024 BST | ||
| 0.91 EUR | -6.19% |
|
| Current month | -9.35% | ||
| 1 month | +27.63% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 04/07/24 | 0.91 | -6.19% |
| 03/07/24 | 0.97 | -1.02% |
| 02/07/24 | 0.98 | -2.00% |
| 01/07/24 | 1 | -6.54% |
| 28/06/24 | 1.07 | +3.88% |
Real-time BOERSE MUENCHEN
Last update July 04, 2024 at 11:25 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Goldman Sachs |
| WKN | GG5971 |
| ISIN | DE000GG59718 |
| Date issued | 14/03/2024 |
| Strike | 1,400 kr |
| Maturity | 20/03/2026 (625 Days) |
| Parity | 10 : 1 |
| Emission price | 0.59 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.11 € |
|---|---|
| Lowest since issue | 0.57 € |
| Spread | 0.05 € |
| Spread % | 5.26% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
967.5
DKK
Average target price
952.2
DKK
Spread / Average Target
-1.59%
- Stock Market
- Warrants
- Warrant
